强心药在心力衰竭应用中的再评价被引量：2

Reassessment of cardiotonic drugs in heart failure

下载PDF

导出

摘要强心药分为洋地黄和非洋地黄药物两类,在200余年的心力衰竭治疗过程中,强心药曾经被作为首选药物,但其对于远期预后影响的循证医学证据不够充分,许多临床试验及事后分析对强心药的远期疗效进行评价,结果颇具争议。由于缺乏循证医学证据的支持,目前强心药物已做为心力衰竭治疗中的最后选择。 Cardiotonic drugs are divided into two categories of digitalis and non-digitalis drugs.Cardiotonic drugs have been used as the first choice drugs in the treatment of heart failure for more than 200 years.However,their evidence for long-term prognosis is not sufficient.Many clinical trials and post hoc analysis of the long-term efficacy of cardiotonic drugs to evaluate,the results are controversial.Due to the lack of evidence-based support,cardiotonic drugs have been used as the final choice in the treatment of heart failure.

作者赵国炎孙跃民 Zhao Guoyan Sun Yuemin(Department of Cardiology, General Hospital of Tianjin Medical University, Tianjin 300052,Chin)

机构地区天津医科大学总医院心内科

出处《临床荟萃》 CAS 2017年第3期189-192,207,共5页 Clinical Focus

关键词强心药地高辛洋地黄属心力衰竭指南 cardiotonic drugs digoxin digitalis heart failure guidebooks

分类号 R541.61 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献2

1刘德敏,崔炜.风雨200年:洋地黄类药物在心力衰竭治疗中的地位[J].临床荟萃,2016,31(9):1033-1037. 被引量：6
2中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122. 被引量：4665

二级参考文献48

1无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量：3671
2Amhrosy AP, Butler J . Ahmed A,et al. The use of digoxinin patients with worsening chronic heart failure: reconsideringan old drug to reduce hospital admissions [ J ]. J Am CollCardiol, 2()14 ,63( 18) : 1823-1832.
3Hashim T, Elbaz S. Patel K. et al. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolicheart failure[j]. Am J Med, 2014 ,127(2) : 132-339.
4Hot hi SS, Chinnappa S. Tan LH. 200 + years of amisunderstood drug for ireating chronic heart failure: digoxin,why and how should we continue using it[j]. Int J Cardiol,2013.168(2):645-647.
5Hopper I. Skiba M. von LTG. et al. Digoxin withdrawalworsens clinical status in stable patients with heart failurereceivingoptimalcontemporaneoustherapy;Arandomizedcontrolled trial[J]. J Card Fail,2015,21(9):779-781.
6Tan DK,Schlosshan D.A new indication for digoxin: toenable introduction and dose escalation of ss blocker therapy insevere heart failure[J]. Int J Cardiol, 2012,158( 1) : 154-155.
7Georgiopoulou VV,Kalogeropoulos A D,Giamouzis G,et al.Digoxin therapy does not improve outcomes in patients withadvanced heart failure on contemporary medical therapy「J ].Circ Heart Fail, 2009,2(2):90-97.
8Freeman JV, Yang J, Sung SH. et al. Effectiveness andsafety of digoxin among contemporary adults with incidenlsystolic heart failure [ J ]. C'ircCardiovascQual Outcomes.2013,6(5):525-533.
9Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy ofdigoxin: systematic review and meta analysis of ohservalionaland controlled trial data[J]. BMJ , 2015,351 :M451.
10Adams KF Jr, (ihali JK, Herbert PJ , et al. A perspective onre-evaluating digoxin' s role in ihe current management ofpatients wilh chronic systolic heart failure: targeting serumconcentration lo reduce hospitalization and improve safelyprofile[J]. Eur J Heart Fail, 2014 ,16(5) :483-493.